ライフサイエンスコーパス: ocular surface disease

1 d goblet cell mucin secretion into tears and ocular surface disease.

2 f wound stability, intraocular fluidics, and ocular surface disease.

3 tory use will strengthen our arsenal against ocular surface disease.

4 rigid gas-permeable lenses in the therapy of ocular surface disease.

5 s damage of the ocular surface epithelium in ocular surface disease.

6 mice, which provide unique models of severe ocular surface disease.

7 ibute to susceptibility to lacrimal gland or ocular surface disease.

8 lenses were collected from patients with no ocular surface disease.

9 or serious ophthalmic complications owing to ocular surface disease.

10 bsent ENaC function in the MG and associated ocular surface disease.

11 developed treatment for patients with severe ocular surface disease.

12 of scleral lens therapy in the management of ocular surface disease.

13 used in the management of moderate to severe ocular surface disease.

14 ropriate treatment, and better management of ocular surface disease.

15 for patients presenting with periorbital and ocular surface disease.

16 accine and therapeutic development for other ocular surface diseases.

17 apeutic target for allergic and inflammatory ocular surface diseases.

18 many potential interventional therapies for ocular surface diseases.

19 cy of doxycycline in treating MMP-9-mediated ocular surface diseases.

20 us serum and RA application in patients with ocular surface diseases.

21 oic acid (RA) have been used to treat drying ocular surface diseases.

22 esis of sterile corneal ulceration and other ocular surface diseases.

23 and doxycycline, a medication used to treat ocular surface diseases.

24 discuss recent advances in MSC for treating ocular surface diseases.

25 ment for patients with end-stage corneal and ocular surface diseases.

26 nctival epithelium in drying and cicatrizing ocular surface diseases.

27 eusis in situ (2 eyes), and undifferentiated ocular surface disease (4 eyes).

28 OOKP procedures were performed for severe ocular surface disease according to the indications and

29 Many of these syndromes can lead to ocular surface disease and are becoming more prevalent a

30 ew and update on recent literature regarding ocular surface disease and corneal refractive surgery.

31 ing body of research that links androgens to ocular surface disease and DED.

32 tear film and tear production abnormalities, ocular surface disease and inflammation, and corneal abn

33 Ocular surface disease and its complications were associ

34 Rapid blinking is associated with worse ocular surface disease and tear stability.

35 Studies involving ocular surface disease and/or keratorefractive (corneal)

36 gh-risk adult patients, including those with ocular surface diseases and multiple graft rejections, a

37 d with greater irritation, tear instability, ocular surface disease, and blink rate.

38 d tear production, accelerated tear breakup, ocular surface disease, and immunopathologic response.

39 hthalmos is an often-overlooked component of ocular surface disease, and its prevalence is likely on

40 -negative ulcers, viral etiology, coexistent ocular surface disease, and multiple grafts were exclude

41 tuberculin skin test status, the presence of ocular surface disease, and the anatomic relationship be

42 ast hope for restoration of vision in severe ocular surface disease, and the retinal surgeon is frequ

43 Glaucoma is associated with significant ocular surface disease, and topical glaucoma therapy bur

44 VR)-induced skin pigmentation, skin cancers, ocular surface disease, and, in some patients, sunburn a

45 ta-thalassemia ocular manifestations include ocular surface disease, as demonstrated by tear function

46 ted therapies may be beneficial for treating ocular surface disease associated with SS.

47 a useful model to examine exocrinopathy and ocular surface disease associated with SS.

48 91 among patients with end-stage corneal and ocular surface diseases at an additional cost of S$67 84

49 The current trend is to diagnose and treat ocular surface disease before cataract surgery using a s

50 r scleral lens therapy for the management of ocular surface disease between June 1, 2006, and Novembe

51 ficial not only in patients with established ocular surface disease, but also in those with minimal s

52 es, such as Meckel syndrome, present several ocular surface disease conditions of unclear pathogenesi

53 onor eyes developed any clinical features of ocular surface disease, conjunctival overgrowth of the d

54 In all patients, vision-threatening ocular surface disease developed as a result of chronic

55 Ocular surface disease due to an autoimmune cause demons

56 r scleral lens therapy were undifferentiated ocular surface disease, exposure keratopathy, and neurot

57 r graft failure (corneal neovascularization, ocular surface disease, glaucoma, active corneal inflamm

58 tative markers of eyelid laxity or secondary ocular surface disease in a sleep clinic population.

59 ible role in the development of exocrine and ocular surface disease in Aire knockout mice.

60 rategies for the diagnosis and management of ocular surface disease in cataract surgery patients are

61 However, OSDI is a poor metric for capturing ocular surface disease in glaucoma because symptoms seem

62 y is a validated questionnaire that assesses ocular surface disease in the context of vision-related

63 trols, at baseline, included mean scores for Ocular Surface Disease Index (31.7 vs 4.1, P < 0.0001),

64 ation including symptom assessment using the Ocular Surface Disease Index (OSDI) and corneal fluoresc

65 In this prospective study, based on the ocular surface disease index (OSDI) and corneal staining

66 al microscopy (IVCM) and were surveyed using Ocular Surface Disease Index (OSDI) and Glaucoma Symptom

67 ptoms of ocular GVHD were assessed using the Ocular Surface Disease Index (OSDI) and Symptom Assessme

68 The Ocular Surface Disease Index (OSDI) is a 12-item scale f

69 Ocular Surface Disease Index (OSDI) questionnaire scores

70 e included as objective metrics, whereas the Ocular Surface Disease Index (OSDI) questionnaire was ad

71 mic assessment including a detailed history, Ocular Surface Disease Index (OSDI) questionnaire, and o

72 f dry eye signs and symptoms composed of the Ocular Surface Disease Index (OSDI) questionnaire, corne

73 Patient symptoms were assessed using the Ocular Surface Disease Index (OSDI) questionnaire.

74 A subset of 689 women completed the Ocular Surface Disease Index (OSDI) questionnaire.

75 eted quality of life was evaluated using the Ocular Surface Disease Index (OSDI) questionnaire.

76 howed 3 of the following 4 dry eye criteria: ocular surface disease index (OSDI) score of more than 1

77 after PROSE fitting using Snellen acuity and Ocular Surface Disease Index (OSDI) survey.

78 Outcome variables were the Ocular Surface Disease Index (OSDI) symptom questionnair

79 al Function Questionnaire (NEI-VFQ), and the Ocular Surface Disease Index (OSDI) were included.

80 of dry eye disease (DED) as assessed by the Ocular Surface Disease Index (OSDI), a 12-item symptom f

81 Demographic information, the Ocular Surface Disease Index (OSDI), and Glaucoma Qualit

82 c tests for dry eye disease (DED), including ocular surface disease index (OSDI), tear breakup time (

83 A symptom questionnaire, the Ocular Surface Disease Index (OSDI), was also administer

84 Symptoms were evaluated using the Ocular Surface Disease Index (OSDI).

85 ar breakup time (TBUT), tear osmolarity, and ocular surface disease index (OSDI).

86 isual-related function subscale score of the Ocular Surface Disease Index (VR-OSDI).

87 in (1) tear osmolarity and (2) DED symptoms (Ocular Surface Disease Index [OSDI] score) between days

88 ich included vision-related quality of life (Ocular Surface Disease Index [OSDI]), clinical examinati

89 Dry eye symptoms (Ocular Surface Disease Index [OSDI]), signs (tear break-

90 ision-related quality-of-life questionnaire (Ocular Surface Disease Index [OSDI]).

91 taining scores [Ora scales]) and subjective (Ocular Surface Disease Index [OSDI], 7-item visual analo

92 mptoms (5-Item Dry Eye Questionnaire [DEQ5], Ocular Surface Disease Index [OSDI], and Neuropathic Pai

93 onjunctival staining, meibomian grading, and Ocular Surface Disease Index and SF-36v2 questionnaires

94 articipants in the PROWL-2 study with normal Ocular Surface Disease Index scores were 44% (95% CI, 38

95 articipants in the PROWL-1 study with normal Ocular Surface Disease Index scores were 55% (95% CI, 48

96 ts have been associated with improvements in Ocular Surface Disease Index scores, a disease-specific

97 Satisfaction with Correction subscales; the Ocular Surface Disease Index's (OSDI's) Symptoms subscal

98 Primary endpoints were mean IOP change and Ocular Surface Disease Index(c) (OSDI) score at each vis

99 inistration of a standardized questionnaire (Ocular Surface Disease Index) and a complete ophthalmolo

100 tear osmolarity (TearLab system), symptoms (Ocular Surface Disease Index), and corneal fluorescein s

101 ng, and an irritation symptom questionnaire (Ocular Surface Disease Index).

102 al rating of eye symptoms, Lee eye subscale, Ocular Surface Disease Index, and Schirmer test.

103 Ocular signs and symptoms (Ocular Surface Disease Index, OSDI) were assessed at day

104 or a clinical diagnosis of dry eye using the Ocular Surface Disease Index, Schirmer tear test, tear b

105 dry eye-related symptoms as measured by the Ocular Surface Disease Index, tear film breakup time, an

106 y where the residents were studied using the Ocular Surface Disease Index, together with diagnostic t

107 cycline, an agent used to treat MMP-mediated ocular surface disease, inhibited the hyperosmolarity-in

108 Ocular surface disease is an important risk factor for g

109 Squamous metaplasia occurs in ocular surface diseases like Sjogren's syndrome (SS).

110 , yeasts were the predominant isolates, with ocular surface disease (OSD) being the leading risk fact

111 The purpose of our study was to compare Ocular Surface Disease (OSD) signs and symptoms of Taflu

112 halmologists treating glaucoma patients with ocular surface disease (OSD).

113 ome of the interesting published research on ocular surface disease over the past year.

114 festations noted were hyperopia and signs of ocular surface disease owing to nocturnal lagophthalmos

115 drainage device (P = .023), and preexisting ocular surface disease (P = .037) were associated with r

116 y of Life 17 (Glau-QoL17) questionnaire, and Ocular Surface Disease Quality of Life (OSD-QoL) questio

117 ional case series performed at a corneal and ocular surface diseases referral center in 2010.

118 In a large cohort of patients with chronic ocular surface disease related to SJS/TEN, PROSE treatme

119 ective device for rehabilitation in advanced ocular surface disease, resulting in a significant impro

120 Clinicians who treat patients with ocular surface disease should be aware of scleral rigid

121 Patients with ocular surface disease still require extra lubrication a

122 Patients with ocular surface disease still require extra lubrication a

123 gery to be performed in patients with severe ocular surface disease such as ocular cicatricial pemphi

124 Keratoconjunctivitis sicca is a common ocular surface disease that develops in patients with aq

125 g normal at birth, develop a chronic form of ocular surface disease that is marked by increased apopt

126 Here, we used a mouse model of ocular surface disease to reveal that commensals were pr

127 h DALK (P = .03) and PKP (P = .002), whereas ocular surface disease was a significant risk factor for

128 Ocular surface disease was significantly more common in

129 Eyelid laxity and ocular surface disease were assessed on bedside ophthalm

130 biotechnology-based treatment agent against ocular surface diseases where endogenous lacritin is ina

131 Dry eye is a complicated ocular surface disease whose exact pathogenesis is not y

132 To treat ocular surface disease with a topical biotherapeutic, th

133 report present advances in the treatment of ocular surface disease with scleral rigid gas-permeable

134 elevant to the clinician in the diagnosis of ocular surface diseases with an increased level of infla